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Abstract 
Previously it has been shown that the extracellular domain of transmembrane BA4 amyloid precursor protein (APP) includes binding sites for 
zinc(I1) and for molecules of the extracellular matrix such as collagen, laminin and the heparin sulfate chains of proteoglycans (HSPGs). Here we 
report that APP also binds copper ions. A copper type I1 binding site was located within residues 135-I 55 of the cysteine-rich domain of APP,,, 
which is present in all eight APP splice isoforms known so far. The two essential histidines in the type II copper binding site of APP are conserved 
in the related protein APLP2. Copper(I1) binding is shown to inhibit homophilic APP binding. The identification of a copper(I1) binding site in APP 
suggests that APP and APLP2 may be involved in electron transfer and radical reactions. 
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1. Introduction 
The /?A4 amyloid precursor protein (APP) and its clos- 
est relative amyloid precursor-like protein 2 (APLP2) are 
multifunctional glycoproteins which both undergo simi- 
lar alternative splicing and are ubiquitously expressed 
(for a recent survey see [1,2]). Only APP is the source of 
the characteristic /3A4 amyloid deposits found in Alz- 
heimer’s disease since the PA4 sequence is not conserved 
in APLP2 [3,4]. 
APP is able to bind to different molecules of the ex- 
tracelluar matrix (ECM) such as collagen, laminin [5,6,7] 
and heparin sulfate side-chains of proteoglycans 
(HSPG’s) [5,8,9]. APP has also been reported to contain 
sequences with growth promoting activity [IO] neurite 
promoting activity [I I] and excitoprotection of neurons 
[I 1,121. 
These activities are conferred by the soluble, non-am- 
yloidogenic secretory products of APP which are gener- 
ated by proteolytic cleavage within the /?A4 region, prox- 
imal to the transmembrane domain of APP [ 13,141. This 
shows that the extracellular part of APP is able to bind 
to molecules of the ECM and suggests that APP may 
participate in cell-cell interaction and cellular growth. 
The binding of APP to heparin sulfate is modulated by 
the APP-ligand zinc(I1) [5]. Zinc(I1) binding was identi- 
fied to correspond to residues 181-200, at the border 
between the cysteine-rich and the acidic domain of APP 
[8,15]. This sequence is included in all eight different APP 
isoforms which are produced by alternative splicing. The 
zinc(I1) binding site is also highly conserved among the 
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three so-far known members of the APP gene family [8]. 
Zinc(I1) is an important cofactor in tissue-remodelling 
and wound-healing and reaches concentrations of 200- 
300 ,uM in brain regions which are damaged in AD and 
reaches similar concentrations in platelets. Since APP is 
highly concentrated at both sites, APP is suggested to be 
involved in repair processes. 
Because tissue damage and subsequent wound-healing 
may be associated with respiratory burst and release of 
free radicals [16,17], and radical attack has been sug- 
gested to be involved in initiation of PA4 amyloid aggre- 
gation [18], we have analysed APP binding to metalions 
such as iron(I1) and copper(I1) that are involved in redox 
reactions. Copper is the third most abundant trace ele- 
ment in humans, after iron and zinc [19]. Since APP did 
not bind to iron(loaded but did bind to copper-loaded 
chelating Sepharose we concentrated on copper(I1) bind- 
ing. We isolated and sequenced a putative type II cop- 
per(I1) binding site of APP. We then determined the 
affinity constant and the influence of copper(I1) binding 
on the homophilic interaction of APP. Our findings of 
a specific type II copper binding site on APP suggests 
that APP-copper binding may participate in electron 
transfer reactions and thus contribute to the aggregation 
and toxicity of /3A4 amyloid. 
2. Experimental 
2.1. Construction of expression vectors 
The plasmids pFd-APP,,,,,,, and pFd-APP770,gA are based on pFd- 
APP [14] and pFd-APP,,,, [8]. To obtain pFd-APP,,,,,, the plasmid 
pFd-APP,,, was linearized with KpnI, treated with alkaline phosphat- 
ase, and religated in the presence of oligonucleotides A and B, 
A: 5’-CGAACCCACGTCCACCAACACCGCTGGAGGTAC-3’ 
B: 5’-CTCCAGCGGTGTTGGTGGACGTGGGTTCGGTAC-3’ 
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which together form cohesive ends complementary to Kpnl restriction 
sites. After transformation of E. coli a colony was selected by polym- 
erase chain reaction containing the plasmid pFd-APP,,,,,, in the de- 
sired orientation. The resulting clone pFd-APP,,,,,, encoded a fusion 
protein with a recognition sequence for the IgA protease from Neisseria 
gonorrhoeae [20,21]. 
The plasmid pFd-APP,,,,,,, was derived from pFd-APP,,,,,, and 
pFd-APP,Z,, by exchanging the corresponding AccI fragments of pFd- 
APP,,,, (6.5 kbp). 
2.2. Purification of APP 
APP,,, was isolated from rat brain (rn-APP) as described previously 
for human brain [22] with the exception that the purification step on 
phenyl-Sepharose was replaced by affinity chromatography on lentil 
lectin-Sepharose. Preparations of purified 130- and 110 kDa APP 
(hs-APP, present as a 1: 1 mixture), were derived from human brain 
membrane extracts and contained soluble holoprotein [22]. 
Full-length (Fd-APP,,, and Fd-APP,,,) recombinant forms and a 
truncated recombinant form of human APP corresponding to the 
N-terminal 262 residues of APP,,, (Fd-APP,,,,) [8] were prepared and 
purified in the form of a prokaryotic expressed Fd fusion protein by 
methods essentially as described by Weidemann et al. [14]. After 
preparative SDS-PAGE and electroelution the soluble protein was sep- 
arated from salts and SDS by Excellulose GF-5 columns (Pierce) and 
renatured in 10 mM Tris-HCl, pH 7.5. 
Fd-APP,,,,,p, and Fd-APP,,,,,, fusion proteins were treated with 
IgA-protease from Neissseria gonorrhoeae at 37°C for 16 h according 
to the manufacturer’s protococ(Boehringer, Mannheim). The cleavage 
products APP,,,, and APP,,, were purified by SDS-PAGE as given for 
Fd-APP,,,,, Fd-APP,,, and Fd-APP,,,. 
Protein concentrations were determined by amino acid analysis. 
2.3. APP binding to Cu(II)-charged chelaring Sepharose 
Human APP was iodinated by the chloramine-T method (Iodo- 
Beads, Pierce) and separated from free iodine by heparin-Sepharose 
chromatography (specific activity: 700,000 cpm/pmol): Increasing con- 
centrations of 1?1APP (100.000 cnmlnmol) were loaded in startine- 
buffer (150 rn$i r\iaCl, Ib mM Tris-Hkl, p’H 7.5) and incubated f& 
2 h at room temperature with 20 ~1 of a 1: 1 suspension of Cu(II)- 
charged chelating Sepharose (Pharmacia) and end-over-end rotation. 
Before incubating with APP, Sepharose has been equilibrated with 
starting-buffer containing 1% ovalbumin, followed b; loading buffer 
(50 mM CuCI,. 10 mM Tris-HCl. DH 6.8) and starting-buffer aeain. 
The amount ofAPP bound was quantified by liquid scin&lation c&nt- 
ing of Sepharose after centrifugation. Values were corrected for non- 
specific binding to Sepharose CL-6B. 
Purified APP fusion proteins were loaded onto a Cu(II)-charged 
chelating Sepharose column (200 ~1 of a 1 : 1 suspension in disposable 
filtration columns (Bakerbond spe), pre-equilibrated as described be- 
fore) in starting-buffer. The column has been washed three times with 
400 ~1 of wash&g-buffer A (400 mM NaCl, 20 mM Tris-HCI, pH 7.5, 
0.05% NP-40). and buffer B (800 mM NaCl. 20 mM Tris-HC1. DH 7.5. 
0.05% NP40) and eluted wit; 100 mM NaCi, 20 mM Tris-HCI: bH 7.5: 
50 mM EDTA. 
Recombinant fusion proteins Fd-APP,,, and Fd-APP,,,, were 
treated with 3 pg of endoproteinase Lys-C (Boehringer, Mannheim) in 
starting-buffer at 37°C overnight. The resulting peptides were incu- 
bated with 300~1 of copper-loaded chelating Sepharose. After washing, 
elution was performed in the presence of EDTA and the eluate was 
dried down. The peptide fraction was redissolved in 5% acetic acid and 
injected onto a RP-HPLC column (Aquapore RP-300, Applied Biosys- 
terns). The peptides were eluted with a linear gradient of 70% acetoni- 
trile in 0.1% TFA. 
2.4. Western blotting of APP 
Western blotting was done as described using the monoclonal anti- 
bodies 22Cll and Al290 (Boehringer, Mannheim) and the problot 
alkaline phosphatase system (Promega) [14]. 
2.5. Homophilic APP binding 
The ‘homophilic’ synthetic peptide (corresponding to residues 448- 
478 of APP,,J (manuscript in preparation) was adsorbed to microtiter 
wells (5fiuglwell) and incubated with 1% BSA in PBS for 1 h, l*SI-labelled 
hs-APP was added (1 x lo3 to 2 x IO6 cpmlwell) together with the diva- 
lent ions to be tested in PBS. After 3 h incubation at room temperature 
the wells were emptied, dried, cut and subjected to liquid scintillation 
counting. 
The mean of duplicate measurements is given which was corrected 
for non-specific binding (BSA alone). 
2.6. Surface plasmon spectroscopy (231 
Surface plasmon resonance analysis (BIAcore, Pharmacia Biosensor) 
of copper(I1) binding was done in 1 x HBS (10 mM HEPES, pH 7.4, 
150 mM NaCI, 0.005% Surfactant P20 (Pharmacia)) at a flow rate of 
5 @/min according to the instructions of the manufacturer. For all 
experiments 2001100 ng of proteins (Clq diluted to 50 &ml, rn-APP 
to 10 pg/ml and Fd-APP,,, and Fd-APP,,,, to 80 @ml in 10 mM 
NaOAc, pH 3.4) were used for couplinn to the CM5 sensor chip 
(BIAcore amine coupling kit) and gaie 9;000-19,000 response units. 
Copper(H) was iniected for 1 min to reach final concentrations of 100 
pM.-Ligands bound to proteins immobilized onto the sensor chip sur- 
face were removed by injecting 30 ~1 of regeneration solution I (I mM 
EDTA, 5 mM DTT, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5) and 20 
~1 of solution II (100 mM HCI). Injections were repeated two times 
independently and the increase of response units taken from the disso- 
ciation phase were averaged. 
Kd value for copper induced structural changes of rn-APP has been 
calculated from equilibrium measurements where the net binding rate 
is zero and association and dissociation are balanced. Using R,, for the 
equilibrium response, substituting K, for k,Jk,,,, and rearranging and 
by plotting R,,IC against R,, K, and R,,, could be calculated from the 
slope and intercept respectively according to: 
R,,/C = K,, x R&intercept) - K, x R,,(slope) 
(see also BIAcore Methods Manual, chapter 8). 
Complement component Clq (human) and hemocyanin (Megathura 
crenulata) were from Sigma, Munich. 
2.7. Peptide synthesis 
Peptides were synthesized according to Barany and Merrifield [24], 
purified on C-l 8 columns with a linear gradient of acetonitrile in 0. I % 
TFA and sequences confirmed using pulse liquid gas phase technology 
and on-line PTH analysis (Applied Biosystems) [25]. 
3. Results 
3.1. APP binding to copper and ident$cation of a 
type II copper binding site 
APP,,, purified from rat brain, recombinant proteins 
APP,,, and APP,,,, (APP residues l-262) bind to 
copper(charged chelating Sepharose. The elution of 
the retained APPs is shown in Figs. 1B and B. The bind- 
ing of APP,,,, places a copper(I1) binding site within the 
N-terminal 262 residues. Binding of [‘251]APP to 
copper(charged chelating Sepharose is saturable (Fig. 
2) at a dissociation constant of 10 nM at pH 7.5 (inset 
of Fig. 2). 
Putative Cu2+ binding sites of APP were identified by 
affinity chromatography of peptides obtained by Endo 
Lys-C digestion of the fusion protein Fd-APP,,,. HPLC 
separation of peptides displaced from the copper-loaded 
column was followed by amino-terminal sequencing. 
The four peptides, Cl, C2, C3, and C4 present in the 
major peaks originated from different positions within 
the APP sequence (Fig. 3). Peptide Cl is encoded within 
exon 9, C4 is encoded within APP exons 9 and 10, C2 
within exon 12 and C3 within exon 4 [26,27]. Only pep- 
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Fig. 1. Copper-charged chelating Sepharose chromatography of APP. (a) Immunostaining of recombinant APP proteins APP,,,, (750 ng loaded, 
lanes 1 and 2) and APP,,, (750 ng loaded, lanes 3 and 4) with monoclonal antibody 22Cl1; eluate (lanes 2 and 4); flow-through (lanes 1 and 3). 
(b) Immunostaining of rn-APP (1 pg loaded, lane 2) and APP,,, (750 ng loaded, lane 4) with monoclonal antibody ALZ90; eluate (lanes 2 and 4); 
flow-through (lanes 1 and 3). ‘loaded’ = amount of proteins applied to the affinity column. 
tide C3 was isolated from APP,,,2 (data not shown). The 
zinc(I1) binding peptide located in exon 5 was not identi- 
fied in both digests (Fig. 3). This shows that the cop- 
per(I1) and zinc(I1) binding is exhibited by different sites. 
Inspection of the four major copper(I1) binding pep- 
tides reveals that Cl, C2 and C3 contain 2 or 4 His 
residues whereas C4 includes a single His residue. Since 
the Endo Lys-C fragments Cl and C3 contained the 
characteristic His-Xxx-His sequence of type II copper 
binding proteins [28] peptides Cl and C3 were synthe- 
sized and found to bind to copper(charged chelating 
Sepharose (data not shown). This His-Xxx-His motif of 
peptide C3 but not of Cl is conserved in APLP2. We 
cpm x 10 -3 
700 -? 
600 -- 
500 -- 
400 -- 
300 -- 
200 -- 
100 -- 
bound/ free 
2.4 
2.2 ;; \ 
1.0 I 
10 100 1000 10000 
APP IPW 
. 
/ 
0 
-< 7 
I 
0.1 1 10 
APP [nM] 
therefore concentrated on peptide C3. The characteris- 
tics of this peptide C3 which is contained within APP,,,, 
are described in this study. 
The amino acid residues of C3 that are responsible for 
binding of copper(I1) were identified with synthetic pep- 
tides carrying the amino acid substitutions indicated in 
Table 1. All of these peptides except mmAPLP1 and 
huAPPNNNNM6 were found to bind to Cu’+. This indi- 
cates that at least two of the histidines found, residues 
13, 15 or 17, have to be conserved, and that one of the 
two adjacent His-Xxx-His motifs is sufficient for the cop- 
per-binding properties of C3. Binding properties of pep- 
tides huAPPS 10, huAPPT7, mmAPLP 1 and 
Fig. 2. Binding of [‘2SI]hs-APP to copper-charged chelating Sepharose. Chelating Sepharose was incubated with [‘*‘I]hs-APP at various concentrations. 
The inset indicates a Scatchard plot for the binding curve. 
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Fig. 3. Reverse-phase chromatography of copper binding peptides obtained by digestion of Fd-APP,,, with endoproteinase Lys-C. Peptides were 
those eluted from chelating Sepharose loaded with copper. N-Terminal sequences of copper binding peptides are given with the numbering of 
APP,,. 
huAPPNNNNM6 show that CyslO and Met7 are not 
essential for copper(I1) binding (Table 1). 
3.2. Regulation of homophilic binding of APP by 
copper (II) 
We used surface plasmon resonance [23] to detect 
changes in the APP conformation in dependence of in- 
creasing concentrations of copper(I1). With this method 
changes in the refractive index of proteins which are 
immobilized to the sensor chip surface can be detected 
if the surface area covered by the protein is altered upon 
binding of a ligand. These changes are expressed in re- 
sponse units (RU) [29]. The surface plasmon resonance 
spectra (sensorgrams) of the binding of copper(I1) to 
purified rat brain APP and to the bacterial fusion pro- 
teins Fd-APP,,, and Fd-APPN262 are shown in Fig. 4. 
These sensorgrams reveal that APP undergoes a confor- 
mational change in the presence of PM copper(I1). 
In a typical experiment injection of copper(I1) to reach 
the final concentration of 100 ,uM resulted in an increase 
from 17400 RU to 17580 RU (Fig. 4, rn-APP), 19000 RU 
to 19300 RU (Fig. 4, Fd-APP,,,,), and 23600 RU to 
24100 RU (Fig. 4, Fd-APP,,,). Upon removal of cop- 
per(H) by EDTA (regeneration solution I) the initial RU 
(baseline) was not reached indicating that an irreversible 
conformational change of APP occurred. A return to 
baseline values was found when DTT was added to the 
regeneration solution I (data not shown). This suggests 
that cystine formation had occured. A formation of S-S 
bridges was also found to occur with the APP peptides 
Table 1 
Binding to copper-charged chelating Sepharose of the synthetic peptide C3 (representing amino acids 1355156 of APP,,), C3 variants and the related 
peptide of APLP2 
Copper binding M, Monomer Dimer 
c3 FLHQE RMDVC ETHLHWHTVAKE 
C3-G5; Gil FLHQGRMDVCGTHLHWHTVAKE 
C3-N3 FLNQE RMDVC ETHLHWHTVAKE 
C3-T7 FLHQE RTDVC ETHLHWHTVAKE 
c3-SIO FLHQE RMDVS ETHLHWHTVAKE 
C3-N13 FLHQE RNDVC ETNLHWHTVAKE 
C3-N17 FLHQE RMDVC ETHLHWNTVAKE 
CS-NNNNM6 FLNQE RTDVS ETNLNWNTVAKE 
C3-N3; N17 FLNQE RMDVC ETHLHWNTVAKE 
C3-N3; T7 FLNQERTDVC ETHLHWHTVAKE 
mm-APLPI FLHQERMDQC ESSTRRHQEAQE 
APLP2 FFHKERMEVC ENHOHWHTWKE 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
n 
Y 
Y 
n 
Y 
2747 Y 
2603 Y 
2727 Y 
2717 Y 
2731 Y 
2724 Y 
2724 Y 
2609 Y 
2701 Y 
2694 Y 
2746 Y 
2851 Y 
Y 
Y 
Y 
Y 
n 
Y 
Y 
n 
Y 
Y 
Y 
Y - 
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Fig. 4. Surface plasmon resonance (SPR) analysis of coppex 
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Fd-APP,,,, hemocyanin and Clq. Results are expressed 
as an increase of relative response units following addition of Cu” (100 ,uM) at time 1.5 mm. 
which bound and were eluted from the copper(II)- 
charged chelating Sepharose (dimerized peptides; Table 
1). 
The increase of APP response units was specific for 
copper(I1) and was not observed for the metal ions Zn’+, 
Co*+, Mn*’ ad Ni2+ (data not shown). A similar increase 
in response units was measured for immobilized hemo- 
cyanin which is a multimeric copper containing protein 
(Fig. 4, hemocyanin). No effect is seen with Clq, a pro- 
tein that does not bind copper(I1) (Fig. 4, Clq). 
The copper(induced reversible structural change of 
rn-APP was used to determine the dissociation constant 
for copper(I1) binding. Equilibrium measurement re- 
vealed a Kd value of 10 PM (Fig. 5). This value falls 
Req / C [RU/pM] 
3 la 
0 1 i 
50 70 90 110 130 150 170 
Req WI 
Fig. 5. Equilibrium measurement analysis of copper binding to APP. Rn-APP was coupled to the sensor chip surface to which Cu’+ was added at 
concentrations of l-100 ,uM and analysed by surface plasmon resonance. 
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Fig. 6. Modulation of binding of the ‘homophilic’ APP peptide to [‘*‘I]hs-APP. Divalent metal ions Zn”, Mg*+, Mn*‘, Co” and Ni2+ (a) and Zn2+, 
Cu*’ and Fe” (b) were added at concentrations of cl00 PM to microtiter wells coated with the ‘homophilic’ APP peptide and [‘251]hs-APP binding 
was analysed. 
within the 20 ,uM range of physiological copper(I1) con- 
centrations [30,31]. 
Because copper(I1) is compared to APP a small ligand 
the contribution of bound copper(I1) for the increment 
of the specific refractive index of the copper(APP 
complex is expected to be negligible. Therefore we con- 
cluded that the copper-induced changes in RU reflect 
primarily structural changes of APP. These structural 
changes could be due to dimerization since a conforma- 
tional change of monomeric APP is unlikely to cause the 
observed RU changes. If dimerization occurs, APP bind- 
ing to an ‘homophilic’ APP peptide (residues 448478 of 
APP,,,) (D. Beher and G. Multhaup, unpublished) 
should be inhibited by copper(I1). This peptide binds to 
APP and is therefore ‘homophilic’. The binding of the 
peptide was analysed in a solid phase assay. Radioiodi- 
nated rat brain APP was added to microtiter plates 
coated with the ‘homophilic’ peptide in the absence or 
presence of copper(I1) and other divalent ions (Fig. 6). 
Binding of [‘*‘I]APP was inhibited by copper(I1) and 
zinc(I1) in a concentration-dependent manner with an 
IC,, at 0.5-l .O PM. This effect was specific for Cu*+ and 
Zn2’ and not observed for other divalent ions such as 
Mg2+, Mn2+, Co*+ and Ni*+ (Fig. 6). 
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4. Discussion 
We found saturable and specific binding of Cu*+ to 
APP. The binding constant was determined to be 10 nM 
which is 3 orders of magnitude below the physiological 
concentration of copper(I1) [30,3 11. Metal affinity 
chromatography of APP fragments obtained after diges- 
tion with Endo-Lys-C resulted four potential copper- 
binding peptides. Sequencing of the four peptides re- 
vealed two (Cl and C3 in Fig. 3) to include the consensus 
His-Xxx-His motif which is characteristic for type II 
copper proteins (Fig. 7). In this study we concentrated 
on peptide C3 since only the sequence of peptide C3 is 
highly conserved in APLP2 (Fig. 7) which is the closest 
relative of APP in the APP gene family [2]. The APLP2 
peptide was synthesized and shown to bind copper(I1). 
The corresponding peptide of APLPl which lacks the 
type11 copper(binding sequence did not bind (Table 
1). Further characterization of peptide C3 was done by 
exchanging histidine, methionine and cysteine residues. 
Dimerization of the peptide upon binding to copper(II)- 
charged chelating Sepharose was not observed when the 
single cysteine residue was replaced by serine. Exchanges 
of the four histidines abolished copper(I1) binding. Cop- 
per(I1) binding was retained in all peptides with an intact 
His-Xxx-His sequence. A substitution of the single 
methionine residue by threonine had no effect on cop- 
per(I1) binding. This confirms that copper binding re- 
quires the presence of histidine residues. 
We then used surface plasmon resonance to analyze 
the effect of copper(binding on APP structure. This 
method allows to monitor ligand binding if the bound 
ligand itself contributes to the changes in light refraction 
(refractive index increment) or if the protein undergoes 
a conformational change upon binding of the ligand. 
Because copper is a small ligand the change observed in 
response units for the APP-copper(II) complex could be 
due to homophilic aggregation or major molecular struc- 
tural changes of APP. The latter appears less likely. We 
therefore analysed the effect of copper(I1) on the binding 
APP695 
APLP2 
LYOX 
SOD 
114 
Fig. 7. Comparison of the copper binding region of APP peptide C3 
with that of the type I1 copper binding proteins human Cu/Zn superox- 
ide dismutase (SOD) and lysyl oxidase (LYOX) and of the correspond- 
ing sequence of APLP2. The proposed Cu” binding regions of APP, 
CulZn superoxide dismutase and lysyl oxidase are boxed. 
of radioiodinated APP to an APP fragment. This frag- 
ment shows homophilic binding to APP. Copper(I1) and 
zinc(I1) were found to inhibit this homophilic binding. 
We showed previously modulation of APP-binding to 
heparin by zinc(I1) to be due to an allosteric effect [32]. 
This conformational change could also interfere with the 
homophilic interaction of APP. Because copper(I1) bind- 
ing causes a significant response in the surface plasmon 
resonance whereas zinc(I1) binding does not, the inhibi- 
tion of the homophilic interaction of APP by copper(I1) 
may be only in part due to conformational changes of the 
monomer. The inhibition by copper(I1) is more likely 
due to the formation of APP aggregates in the presence 
of copper(I1). This aggregation appears to involve or 
mask the homophilic binding site of APP and inhibit the 
binding to the peptide on the solid support. 
The presence of a type II copper-binding site in APP 
suggests that APP belongs to the same group of proteins 
to which the copper protein superoxide dismutase and 
lysyl oxidase belong. APP may therefore have a function 
in electron transfer and radical reactions. 
It remains to be shown whether this putative APP 
function is altered in Alzheimer’s disease and whether 
APP thus could contribute to the suggested radical-medi- 
ated initiation of /?A4 amyloid aggregation [18]. 
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